-
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
-
ADMA Biologics Investors Should Contact Block & Leviton By August 10th to Lead Class Action Lawsuit
-
Raymond James Starts ADMA Biologics (ADMA) at Outperform
-
ADMA Biologics Investors Should Contact Block & Leviton to Possibly Recover Losses Through The Firm's Investigation
-
ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors
-
ADMA Biologics Investigated for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
-
ADMA Biologics (ADMA) Misses Q1 EPS by 1c, Offers Guidance
-
Increasing unusual call option volume: ADMA CANE DBA PTEN PRCT COUR JBS
-
ADMA Biologics refutes short seller allegations about products
-
ADMA Biologics (ADMA) June 10 and 15 calls active, share price down 18.4%
-
Increasing unusual call option volume: ADMA MLCO ESTC NEXT BZAI JBS CHPT NAVN TERN
-
Cantor Fitzgerald Downgrades ADMA Biologics (ADMA) to Neutral
-
ADMA Biologics disputes short-seller report claims
-
ADMA Biologics shares plunge on short seller allegations
-
Culper Research is short ADMA Biologics (ADMA)
-
ADMA Biologics (ADMA) Tops Q4 EPS by 1c ; Offers Guidance
-
ADMA Biologics reports $510-511 million 2025 revenue, raises 2026 outlook
-
ADMA Biologics (ADMA) call put ratio 1 call to 4.2 puts with a focus on January 17, 18 and 19 puts
-
These stocks are new additions to Mizuho's 'Americas Top Picks' list
-
ADMA Biologics (ADMA) Reports In-Line Q3 EPS, provides guidance
-
ADMA Biologics (ADMA) Misses Q2 EPS by 1c
-
Increasing unusual put option volume: ADMA ASPN MSOS PR BE FLNC CVE GXO TAP AXON
-
ADMA Biologics (ADMA) Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
-
ADMA Biologics (ADMA) spreader of 3K contracts of April 19 and May 22 calls as share price up 4.3%
-
ADMA Biologics (ADMA) Issues Statement on Tariffs
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
ADMA Biologics (ADMA) PT Raised to $32 at Mizuho
-
Cantor Fitzgerald Reiterates Overweight Rating on ADMA Biologics (ADMA)
-
ADMA Biologics (ADMA) Tops Q4 EPS by 31c, Offers Guidance
-
Options with decreasing option implied volatility: MNKD AEHR AUR GME IRBT ADMA CONY
-
ADMA Biologics (ADMA) PT Raised to $28 at Mizuho
-
Mizuho Reiterates Outperform Rating on ADMA Biologics (ADMA)
-
ADMA Biologics (ADMA) call put ratio 1.6 calls to 1 put on active options volume of 16K contracts
-
Mizuho Reiterates Outperform Rating on ADMA Biologics (ADMA)
-
ADMA Biologics (ADMA) Tops Q3 EPS by 2c
-
H.C. Wainwright Reiterates Buy Rating on ADMA Biologics (ADMA)
-
Mizuho Healthcare Desk Distributes Comments on ADMA Biologics (ADMA) Weakness Post Call, Shares Down ~20%
-
ADMA Biologics (ADMA) to Join S&P SmallCap 600 Index
-
Zurn Elkay Water, Clear Secure, TG Therapeutics, others to join S&P SmallCap 600
-
ADMA Biologics (ADMA) Announces Partial Paydown of Revolving Credit Facility
-
ADMA Biologics (ADMA) PT Raised to $18 at H.C. Wainwright
-
ADMA Biologics (ADMA) Tops Q2 EPS by 5c ; Offers Guidance
-
ADMA Biologics (ADMA) PT Raised to $14 at Mizuho

